Anticancer research · 2011
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dohi Satoshi, Ohno Satoshi, Ohno Yumiko, Takakura Masahiro, Kyo Satoru, Soma Gen-Ichiro, Sugiyama Haruo, Inoue Masaki
Аннотация
UNLABELLED: We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
CASE REPORT: Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
CASE REPORT: Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
Предметные рубрики MeSH
Adjuvants, ImmunologicBiomarkers, TumorCA-125 AntigenCancer VaccinesCarboplatinClinical Trials, Phase II as TopicCombined Modality TherapyCystadenocarcinoma, SerousDocetaxelFemaleHLA-A AntigensHLA-A24 AntigenHumansImmunotherapy, ActiveMembrane ProteinsMiddle AgedOmentumOvarian NeoplasmsPaclitaxelPeptide FragmentsPeritoneal NeoplasmsTaxoidsTumor BurdenVaccines, SubunitWT1 Proteins